You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 8, 2025

OPTIRAY 320 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Optiray 320 patents expire, and when can generic versions of Optiray 320 launch?

Optiray 320 is a drug marketed by Liebel-flarsheim and is included in two NDAs.

The generic ingredient in OPTIRAY 320 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OPTIRAY 320?
  • What are the global sales for OPTIRAY 320?
  • What is Average Wholesale Price for OPTIRAY 320?
Drug patent expirations by year for OPTIRAY 320
Recent Clinical Trials for OPTIRAY 320

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke Clinical Research InstitutePhase 4
GE HealthcarePhase 4
BayerPhase 4

See all OPTIRAY 320 clinical trials

Pharmacology for OPTIRAY 320

US Patents and Regulatory Information for OPTIRAY 320

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 019710-001 Dec 30, 1988 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 2 of 2 entries

Expired US Patents for OPTIRAY 320

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 019710-001 Dec 30, 1988 4,396,598 ⤷  Subscribe
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998 4,396,598 ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 2 of 2 entries

International Patents for OPTIRAY 320

See the table below for patents covering OPTIRAY 320 around the world.

CountryPatent NumberTitleEstimated Expiration
Australia 9151182 ⤷  Subscribe
Canada 1198739 DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE) ⤷  Subscribe
Germany 3362967 ⤷  Subscribe
Japan S58131970 COMPOUND ⤷  Subscribe
Japan H0224252 ⤷  Subscribe
Netherlands 930067 ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 6 of 6 entries

Supplementary Protection Certificates for OPTIRAY 320

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
0083964 93C0142 Belgium ⤷  Subscribe PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016
0083964 SPC/GB93/089 United Kingdom ⤷  Subscribe SPC/GB93/089: 20041015
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 2 of 2 entries

OPTIRAY 320 Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for OPTIRAY 320 (Ioversol Injection 68%)

Introduction to OPTIRAY 320

OPTIRAY 320, also known as ioversol injection 68%, is a nonionic, lower osmolar, and lower viscosity contrast agent widely used in medical imaging procedures such as CT scans, X-rays, and angiography. Here, we delve into the market dynamics and financial trajectory of this crucial medical product.

Market Segmentation

The ioversol market, which includes OPTIRAY 320, is segmented based on several key factors:

By Products

  • The market includes various concentrations of ioversol, such as Ioversol 34% Injectable Solution (Optiray 160), Ioversol 51% Injectable Solution (Optiray 240), Ioversol 64% Injectable Solution (Optiray 300), Ioversol 68% Injectable Solution (Optiray 320), and Ioversol 74% Injectable Solution (Optiray 350)[1][4].

By Applications

  • OPTIRAY 320 is used in a broad range of medical imaging applications, including X-ray, CT scans, brain disorders, blood vessel disorders, heart disorders, and other diagnostic procedures[1][3].

By Key Players

  • The market is dominated by several key players, including Jiangsu Hengrui Medicine Co, Mallinckrodt Pharmaceuticals, Liebel-Flarsheim Company LLC, Ultraject, and Guerbet. These companies employ various strategies such as acquisitions, mergers, and regional expansion to maintain their market share[1].

Market Size and Growth

Current Market Size

  • As of 2023, the global ioversol market, which includes OPTIRAY 320, was valued at approximately $0.49 billion[4].

Forecasted Growth

  • The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.22% and reach $0.86 billion by 2031. This growth is driven by increasing demand for advanced diagnostic imaging procedures and the expanding healthcare infrastructure globally[4].

Regional Analysis

North America

  • North America is forecasted to occupy a major share in the ioversol market. Countries like the U.S., Canada, and Mexico are key contributors due to their advanced healthcare systems and high adoption rates of diagnostic imaging technologies[1][4].

Europe

  • Europe is another significant region, with countries such as Germany, the U.K., France, Italy, and Spain contributing substantially to the market. The region's well-developed healthcare sector and high demand for diagnostic imaging drive the growth here[4].

Asia Pacific (APAC)

  • The APAC region, including countries like China, India, Japan, and South Korea, is also experiencing rapid growth. This is due to the increasing healthcare expenditure and the growing need for advanced diagnostic tools in these countries[1].

Competitive Landscape

The ioversol market, including OPTIRAY 320, is highly competitive with multiple significant players. These companies are engaged in various inorganic growth strategies such as acquisitions and mergers to expand their market share and gain a competitive edge.

Product Features and Safety Profile

Product Characteristics

  • OPTIRAY 320 is a lower osmolar, lower viscosity, nonionic contrast agent. It is available in various packaging configurations, including syringes, vials, and bottles, and is part of a fully integrated contrast media delivery system that enhances efficiency in CT imaging[2][3].

Safety Profile

  • OPTIRAY 320 has a good safety profile, with fewer changes in cardiac function and systemic blood pressure compared to conventional ionic media. It is biologically inert when injected into the body for diagnostic purposes and has been used in over 140 million doses since its introduction in 1989[2][3].

Financial Performance and Strategies

Revenue Streams

  • The revenue for OPTIRAY 320 and other ioversol products is generated through sales in various regions. The market is driven by the increasing demand for diagnostic imaging procedures, which in turn drives the sales of contrast agents like OPTIRAY 320.

Market Strategies

  • Key players in the market focus on strategic expansions, product innovations, and partnerships to maintain their market position. For instance, the integration of RFID technology in prefilled syringes and the use of advanced contrast delivery systems are examples of such strategies[2].

Key Takeaways

  • Market Growth: The ioversol market, including OPTIRAY 320, is expected to grow significantly, reaching $0.86 billion by 2031.
  • Regional Dominance: North America is forecasted to hold a major share in the market, followed by Europe and the APAC region.
  • Product Safety: OPTIRAY 320 has a strong safety profile, making it a preferred choice for various diagnostic imaging procedures.
  • Competitive Landscape: The market is highly competitive, with key players employing various strategies to maintain their market share.

FAQs

Q: What is OPTIRAY 320 used for?

  • OPTIRAY 320 is used for contrast-enhanced computed tomographic imaging, X-ray, angiography, and other diagnostic procedures to enhance the visibility of internal body structures.

Q: Who are the key players in the ioversol market?

  • Key players include Jiangsu Hengrui Medicine Co, Mallinckrodt Pharmaceuticals, Liebel-Flarsheim Company LLC, Ultraject, and Guerbet.

Q: What is the expected growth rate of the ioversol market?

  • The ioversol market is expected to grow at a CAGR of 7.22% from 2023 to 2031.

Q: What are the main regions contributing to the ioversol market?

  • The main regions include North America, Europe, and the Asia Pacific (APAC).

Q: What are the safety features of OPTIRAY 320?

  • OPTIRAY 320 has a lower osmolar and lower viscosity profile, causing fewer changes in cardiac function and systemic blood pressure compared to conventional ionic media.

Sources

  1. Market Research Store: Ioversol Market Size, Share, Industry Growth Analysis Report.
  2. MXR Imaging: Optiray 320 (Ioversol Injection 68%).
  3. NCBI: 320 Optiray® Pharmacy Bulk Package.
  4. FutureWise Research: Ioversol Market Overview.
  5. Mayo Clinic: Ioversol (injection route).

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.